Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I will reveal the best growth stock to buy in this market.

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor13 Aug 2025, 22:21 UTC
Video preview for Friends! In this video, I will reveal the best growth stock to buy in this market.
Signals
2
Eligible signals in this source
Open
0
Still being tracked
Resolved
2
Evaluable outcomes
Successful
2
Canonical correct result
Failed
0
Canonical failed result
Resolved success
100%
Open and excluded signals omitted
Source overview

AI-generated source summary

The presenter discusses two growth stocks, SOFI, currently priced at $23.65, the presenter predicts will reach $32.00 within a year, and HIMS, as of the current date trading at $47.96, the presenter estimates a target value of $65.00 within the next year, due to GLP-1 and telehealth opportunities. He supports that HIMS having a great potential and profitability with revenue estimates pointing to a growth is coming in a way to be considered a non factor to be ignored. He also stated that the fail bound to HIMS would be around 40 dollars.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    2 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.